Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_066c291041ab22f89d2159670edd4ee8 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 |
filingDate |
1994-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eeaec5d280371f0007d0eb78b41ce253 |
publicationDate |
1996-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-0700293-A1 |
titleOfInvention |
Dihydrotestosterone for use in androgenotherapy |
abstract |
Composition for use in androgenotherapy and having a favorable effect on the prostate hyperplasia. The composition is characterized in that it contains dihydrotestosterone in an administered quantity corresponding to a level of dihydrotestosterone alone greater than 2.5 ng/ml and to a total plasmatic testosterone and dihydrotestosterone level greater than 3.5 ng/ml in an average male. |
priorityDate |
1993-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |